[Chronic autoimmune hemolytic anemia: toward new treatments?].
Bader-Meunier
B
B
Service de pédiatrie générale, hôpital de Bicêtre, Le-Kremlin-Bicêtre, France. brigitte.bader-meunier@bct.aphp.fr
Leverger
G
G
D000744:Anemia, Hemolytic, Autoimmune / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D001685:Biological Factors / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004910:Erythrocyte Membrane / Q000276:immunology; D005500:Follow-Up Studies; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D001685:Biological Factors; D007166:Immunosuppressive Agents; D000069283:Rituximab; D007168:IMP Dehydrogenase; C488211:IMPDH1 protein, human; D009173:Mycophenolic Acid